
The Federal Circuit Upholds Drug Dosing Regimen as Valid and Nonobvious
In Janssen Pharmaceuticals, Inc. v. Mylan Laboratories., the United States Court of Appeals for the Federal Circuit affirmed a district court ruling that a pharmaceutical dosing claim limitation was nonobvious despite prior art describing dosing regimens …